Log in
E-mail
Password
Show password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON
  1. Homepage
  2. Equities
  3. Switzerland
  4. Swiss Exchange
  5. Roche Holding AG
  6. News
  7. Summary
    ROG   CH0012032048

ROCHE HOLDING AG

(ROG)
  Report
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector newsMarketScreener Strategies

Roche : family shareholders will maintain stability - vice chairman

10/17/2021 | 05:28am EST
FILE PHOTO: Logo of Swiss pharmaceutical company Roche is pictured in Rotkreuz

ZURICH (Reuters) - The head of Roche's controlling group of shareholders is "very confident" stability can be maintained at the pharmaceuticals company after the next generation of heirs joined the family pool of investors, he told NZZ am Sonntag.

"The new generation has the same values as the older family members," Andre Hoffmann, the great grandson of the company's founder, told the newspaper in an article published on Sunday.

"Our role as the owner family is to enable Roche to focus on creating sustainable values over the long term. We are convinced of that," said the 63-year-old, who is spokesman for the pool of family members that controls 45.01% of the Basel company.

A pooling agreement between the descendants of company founder Fritz Hoffmann-La Roche has existed since 1948, and was extended for an indefinite period in 2009. A fifth generation was admitted to the pool in 2019.

Hoffmann, who is also a vice chairman of Roche, said family ownership of large companies did not always work.

"If it works, it is a great strength for the company. If not, it can be diabolical," he said.

(Reporting by John Revill; Editing by Jan Harvey)


ę Reuters 2021
All news about ROCHE HOLDING AG
08:12aREMINDER : Invitation to Roche's virtual event on key hematology data presented at ASH 202..
PU
04:18aCHMP Recommends EU Approval of Chugai's Actemra, RoActemra to Treat Patients with Sever..
AQ
12/07Roche, Genentech Join Recursion Pharmaceuticals to Advance Neuroscience, Oncology Medic..
MT
12/07Recursion Pharmaceuticals Sets Drug-Discovery Pact With Roche, Genentech
DJ
12/07EU Authorizes Roche's Arthritis Medicine for Treatment of Severe COVID-19
MT
12/07PTC Therapeutics, Inc. - Evrysdi Distinguished by Two Prestigious Awards for Outstandin..
AQ
12/07EU Approves Roche's Actemra/RoActemra Against Severe Covid-19
DJ
12/07Actemra/RoActemra approved by the European Commission to treat patients with severe COV..
AQ
12/07ROCHE HOLDINGS AG : Jefferies keeps its Buy rating
MD
12/07Roche Rolls Out AI-Based Algorithms to Evaluate Breast Cancer Markers
MT
More news
Analyst Recommendations on ROCHE HOLDING AG
More recommendations
Financials
Sales 2021 62 197 M 67 553 M 67 553 M
Net income 2021 15 305 M 16 622 M 16 622 M
Net cash 2021 3 944 M 4 283 M 4 283 M
P/E ratio 2021 20,4x
Yield 2021 2,51%
Capitalization 304 B 329 B 330 B
EV / Sales 2021 4,82x
EV / Sales 2022 4,71x
Nbr of Employees 101 465
Free-Float 83,5%
Chart ROCHE HOLDING AG
Duration : Period :
Roche Holding AG Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends ROCHE HOLDING AG
Short TermMid-TermLong Term
TrendsBullishBullishBullish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 24
Last Close Price 372,90 CHF
Average target price 388,97 CHF
Spread / Average Target 4,31%
EPS Revisions
Managers and Directors
Severin Schwan Chief Executive Officer & Executive Director
Alan Hippe Chief Financial & Information Officer
Christoph Franz Chairman
Pascale Schmidt Chief Compliance Officer
AndrÚ S. Hoffmann Vice Chairman
Sector and Competitors
1st jan.Capi. (M$)
ROCHE HOLDING AG19.17%324 115
JOHNSON & JOHNSON3.80%430 061
PFIZER, INC.39.85%290 297
NOVO NORDISK A/S70.26%250 392
ELI LILLY AND COMPANY45.17%222 215
ABBVIE INC.13.40%214 815